NDC product
Everolimus
NDC 0054-0481 · Hikma Pharmaceuticals USA Inc.
Key facts
| Product NDC | 0054-0481 |
|---|---|
| Proprietary name | Everolimus |
| Nonproprietary name | Everolimus |
| Substances | EVEROLIMUS |
| Dosage form | TABLET |
| Route | ORAL |
| Labeler | Hikma Pharmaceuticals USA Inc. |
| Product type | HUMAN PRESCRIPTION DRUG |
| Marketing category | ANDA |
| Application number | ANDA207486 |
| Pharmacologic classes | Cytochrome P450 2D6 Inhibitors [MoA], Cytochrome P450 3A4 Inhibitors [MoA], Decreased Immunologic Activity [PE], Kinase Inhibitor [EPC], Protein Kinase Inhibitors [MoA], mTOR Inhibitor Immunosuppressant [EPC] and 1 more |
| Marketing start | Jun 8, 2020 |
| Listing certified through | Dec 31, 2027 |
At a glance
- 1–9 Package NDCs
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About National Drug Codes (NDC)
The National Drug Code (NDC) is the FDA's product identifier for drugs; the product NDC identifies the labeler and product, and each package adds a package code.
Source: U.S. Food and Drug Administration (FDA), National Drug Code Directory · Source date: